What We're Reading: Page 209
Industry reads hand-picked by our editors
Sep 10, 2019
Sep 09, 2019
-
Los Angeles Times
An FDA insider's view of where medical innovation falls short
-
ProPublica
Data Touted by OxyContin Maker to Fight Lawsuits Doesn't Tell the Whole Story
-
The New York Times
The challenge of identifying Sjogren's syndrome
-
The Dallas Morning News
When opioids go missing, hospitals are supposed to alert the DEA. That didn’t happen at UT Southwestern
Sep 06, 2019
-
Reuters
Inside drugmakers' strategy to boost cancer medicines with 'Lazarus effect'
-
The Wall Street Journal
A Turn for the Worse for Biotech Stocks
-
C&EN
Gut bacteria feast on the pills we pop
Sep 05, 2019
-
The Wall Street Journal
Texas Doctor Stephen M. Hahn Is a Top Contender to Head FDA
-
Reuters
Novartis sees cell, gene therapy reaching up to 15% of sales in midterm
-
The New York Times
Johns Hopkins Opens New Center for Psychedelic Research
-
The Boston Globe
Did a biotech exec crib a New Yorker cartoon?
Sep 04, 2019
Sep 03, 2019
-
Barron's
mRNA Is the Next Frontier in Treating Disease. But Will It Work?
-
The Wall Street Journal
Ohio Attorney General Seeks Delay of Landmark Opioid Trial
-
The Washington Post
Rare childhood disease prompts family to seek cure
-
MarketWatch
AstraZeneca shares hit record after Farxiga study
Aug 30, 2019
-
The Wall Street Journal
Proposed Opioid Deal With Purdue Drawing Pushback From States
-
Bloomberg
Juul Seizure Reports Prompt FDA Probe into E-Cigarettes
-
Endpoints News
On track for first autoimmune drug approval, Bing Yao steers AstraZeneca spinoff to $150M IPO
-
STAT
Vaccine coalition unveils ambitious plan to immunize 300 million children
Previous
